I normally don’t get excited about a drug which is just beginning Phase 2 but I am rooting for this one. The promises sure are great and I am glad someone is doing something other than turning an old med into a injectable.
1 Like
Karuna Therapeutics is scheduled to meet with U.S. regulators in the second quarter of 2020 and expects to initiate a phase 3 trial evaluating KarXT as a treatment for acute psychosis in schizophrenia by the end of 2020. The company also expects to begin phase 1b trials for the drug candidate in pain indications and psychosis in Alzheimer’s by the end of 2019, followed by two phase 1b trials for different symptoms in schizophrenia [cognitive and negative] by the end of the first half of 2020.
1 Like
I hope it comes effective for negative and cognitive symptoms…!!
1 Like